Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

    loading  Checking for direct PDF access through Ovid


Article abstract

Sixteen patients with amyotrophic lateral sclerosis (ALS) participated in a double-blind, placebo-controlled study using tilorone hydrochloride, a drug active against a variety of DNA and RNA viruses in animals. On the basis of neurologic examination, pulmonary function studies, quantitative muscle examination, speech recording, and periodic filming of functional muscle strength, it was concluded that at a dose of 1 gm per week, tilorone did not alter the course of ALS.

Related Topics

    loading  Loading Related Articles